Kura Oncology, Inc.
Substituted inhibitors of menin-MLL and methods of use

Abstract:

The present disclosure provides compounds of Formula (II-A), ##STR00001## which inhibit the interaction of menin with one or more of MLL1, MLL2 and MLL-fusion oncoproteins. Also disclosed are methods for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.